ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Metrics to compare | ORIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORICPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.1x | −3.3x | −0.6x | |
PEG Ratio | −0.32 | 0.03 | 0.00 | |
Price / Book | 2.2x | 2.3x | 2.6x | |
Price / LTM Sales | - | 24.7x | 3.2x | |
Upside (Analyst Target) | 97.7% | 184.1% | 41.1% | |
Fair Value Upside | Unlock | 16.9% | 5.9% | Unlock |